4.7 Review

Classification of primary progressive aphasia and its variants

期刊

NEUROLOGY
卷 76, 期 11, 页码 1006-1014

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31821103e6

关键词

-

资金

  1. National Institute of Neurological Disorders and Stroke [R01NS050915]
  2. National Institute on Aging [P50AG023501, P01 AG019724, RO1 AG15866, U24 AG26395]
  3. National Institute on Deafness and Communication Disorders [DC008552]
  4. National Institute on Aging (Alzheimer Disease Center) [AG13854]
  5. NIDCD [DC008552, AG17586, AG15116, NS44266, NS53488]
  6. Wellcome Trust
  7. Brain Exit Scholarship [R01AG034499-02]
  8. NIH [ROI NS047691, RO1DC05375]
  9. Alzheimer's Association [IIRG-05-14560]
  10. Australian Research Council Federation
  11. NIH (NINDS, NIA)
  12. John Douglas French Alzheimer's Foundation
  13. Alzheimer's Association
  14. Larry L. Hillblom Foundation
  15. Koret Family Foundation
  16. McBean Family Foundation
  17. NIH (NINDS, NIDCD)
  18. NIH (NIA, NIDCD)
  19. Elan Corporation, Pfizer Inc.
  20. Lundbeck Inc.
  21. Lawson Research Institute
  22. American Neurological Society
  23. Whitaker professorship
  24. Human Brain Mapping and on the Advisory Boards of the Cure Alzheimer Fund
  25. Association for Frontotemporal Dementia
  26. NIH
  27. Brain Exit Scholarship
  28. Pfizer Inc.
  29. Eisai Inc.
  30. Myriad Genetics, Inc.
  31. Cephalon, Inc.
  32. US Department of Veterans Affairs
  33. GE Healthcare
  34. Eli Lilly and Company
  35. Medivation, Inc.
  36. Novartis
  37. Research Foundation Flanders
  38. Interuniversity Attraction Pole, KU Leuven [P6/29]
  39. Stichting Alzheimer Onderzoek

向作者/读者索取更多资源

This article provides a classification of primary progressive aphasia (PPA) and its 3 main variants to improve the uniformity of case reporting and the reliability of research results. Criteria for the 3 variants of PPA-nonfluent/agrammatic, semantic, and logopenic-were developed by an international group of PPA investigators who convened on 3 occasions to operationalize earlier published clinical descriptions for PPA subtypes. Patients are first diagnosed with PPA and are then divided into clinical variants based on specific speech and language features characteristic of each subtype. Classification can then be further specified as imaging-supported if the expected pattern of atrophy is found and with definite pathology if pathologic or genetic data are available. The working recommendations are presented in lists of features, and suggested assessment tasks are also provided. These recommendations have been widely agreed upon by a large group of experts and should be used to ensure consistency of PPA classification in future studies. Future collaborations will collect prospective data to identify relationships between each of these syndromes and specific biomarkers for a more detailed understanding of clinicopathologic correlations. Neurology (R) 2011;76:1006-1014

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据